The biotechnology Leukos Biotech and the bioinformatics Mind The Byte, a CataloniaBio members, have reached an agreement to work on the development of potential treatments for the T-cell acute lymphoblastic leukemia (T- ALL), that represents a 15% of all cases of leukemia.
The project will be based on previous studies developed by the Leukemia Stem Cells Group at the Josep Carreras Leukemia Research Institute, led by Dr Ruth Risueño. Risueño is co-founder and CSO of Leukos Biotech. These studies have discovered the therapeutic effect of several molecules, but their mechanism of action remains unknown. Mind the Byte will computationally investigate the interactions and specific molecular targets of those candidates. "Discovering the mechanism of action of these potential drugs can lead to the improvement of their efficacy and safety," says Dr Risueño. The combination of the different bioinformatics tools developed by Mind the Byte will help accelerate the project and potentially get to the clinical phase faster.
Photo: Dr. Alfons Nonell-Canals, CEO of Mind the Byte, and Dr. Ruth Riuseño, CSO of Leukos Biotech.
Comments